Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT

Journal of the American College of Cardiology

Volumn 73, Issue 22, 2019, Pages 2791-2802

  Bhatt, Deepak L ^a   Steg, Ph Gabriel ^b,c   Miller, Michael ^d   Brinton, Eliot A ^e   Jacobson, Terry A ^f   Ketchum, Steven B ^g   Doyle, Ralph T ^g   Juliano, Rebecca A ^g   Jiao, Lixia ^g   Granowitz, Craig ^g   Tardif, Jean Claude ^h   Gregson, John ⁱ   Pocock, Stuart J ⁱ   Ballantyne, Christie M ^j  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BICHAT HOSPITAL   (France)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e Utah Lipid Center   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Amarin Pharma   (United States)

^h MONTREAL HEART INSTITUTE   (Canada)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

more..

Author keywords

eicosapentaenoic acid; icosapent ethyl

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID ETHYL ESTER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ANTITHROMBOCYTIC AGENT; ICOSAPENTAENOIC ACID;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE BURDEN; DRUG EFFECT; FRAILTY; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY (TOPIC); POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; UNSTABLE ANGINA PECTORIS; AGED; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL RATE;

AGED; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RISK FACTORS; SURVIVAL RATE;

EID: 85065549429     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2019.02.032     Document Type: Article

References (57)

1. Bhatt, D.L., Steg, P.G., Ohman, E.M., et al., for the REACH Registry Investigators. International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006), 180–189.
2. Steg, P.G., Bhatt, D.L., Wilson, P.W.F., et al., for the REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 (2007), 1197–1206.
3. Bhatt, D.L., Eagle, K.A., Ohman, E.M., et al., for the REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304 (2010), 1350–1357.
4. Cavender, M.A., Steg, P.G., Smith, S.C., et al., for the REACH Registry Investigators. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH)registry. Circulation 132 (2015), 923–931.
5. Roe, M.T., Armstrong, P.W., Fox, K.A.A., et al., for the TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367 (2012), 1297–1309.
6. Bakal, J.A., Roe, M.T., Ohman, E.M., et al. Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. Eur Heart J 36 (2015), 385–392.
7. Cannon, C.P., Braunwald, E., McCabe, C.H., et al., for the PROVE IT-TIMI 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004), 1495–1504.
8. Miller, M., Cannon, C.P., Murphy, S.A., et al., for the PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol 51 (2008), 724–730.
9. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al., for the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
10. Murphy, S.A., Cannon, C.P., Blazing, M.A., et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome. J Am Coll Cardiol 67 (2016), 353–361.
11. Szarek, M., White, H.D., Schwartz, G.G., et al., for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab reduces total nonfatal cardiovascular and fatal events in the ODYSSEY OUTCOMES trial. J Am Coll Cardiol 73 (2019), 387–396.
12. Libby, P., Triglycerides on the rise: should we swap seats on the seesaw?. Eur Heart J 36 (2015), 774–776.
13. Ganda, O.P., Bhatt, D.L., Mason, R.P., Miller, M., Boden, W.E., Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol 72 (2018), 330–343.
14. Ference, B.A., Kastelein, J.J.P., Ray, K.K., et al. Association of triglyceride-lowering LPL variants and LDL-C–lowering LDLR variants with risk of coronary heart disease. JAMA 321 (2019), 364–373.
15. Bays, H.E., Ballantyne, C.M., Kastelein, J.J., Isaacsohn, J.L., Braeckman, R.A., Soni, P.N., Eicosapentaenoic acid ethyl ester (AMR101)therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE]trial). Am J Cardiol 108 (2011), 682–690.
16. Ballantyne, C.M., Bays, H.E., Kastelein, J.J., et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101)therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 110 (2012), 984–992.
17. Yokoyama, M., Origasa, H., Matsuzaki, M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 369 (2007), 1090–1098.
18. Mason, R.P., Jacob, R.F., Shrivastava, S., Sherratt, S.C.R., Chattopadhyay, A., Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta 1858 (2016), 3131–3140.
19. Watanabe, T., Ando, K., Daidoji, H., et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol 70 (2017), 537–544.
20. Bhatt, D.L., Steg, P.G., Miller, M., et al., on behalf of the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380 (2019), 11–22.
21. Picard, F., Bhatt, D.L., Ducrocq, G., et al. Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease. An analysis from the CLARIFY registry. J Am Coll Cardiol 73 (2019), 1362–1364.
22. Bhatt, D.L., Steg, P.G., Brinton, E.A., et al. Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial. Clin Cardiol 40 (2017), 138–148.
23. Bhatt, D.L., Fox, K.A.A., Hacke, W., et al., for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006), 1706–1717.
24. Cannon, C.P., Braunwald, E., McCabe, C.H., et al., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004), 1495–1504.
25. Ginsberg, H.N., Elam, M.B., Lovato, L.C., et al., for the ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1563–1574.
26. Colhoun, H.M., Betteridge, D.J., Durrington, P.N., et al., on behalf of the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial. Lancet 364 (2004), 685–696.
27. Pedersen, T.R., Faergeman, O., Kastelein, J.J., et al., for the IDEAL Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005), 2437–2445.
28. Patel, A., Macmahon, S., Chalmers, J., et al., for the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
29. Braunwald, E., Domanski, M.J., Fowler, S.E., et al., for the PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004), 2058–2068.
30. Boden, W.E., Probstfield, J.L., Anderson, T., et al., for the AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
31. Green, J.B., Bethel, M.A., Armstrong, P.W., et al., for the TECOS Study Group. Effect of sitagliptin on vardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
32. Landray, M.J., Haynes, R., Hopewell, J.C., et al., for the HPS-2 THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371 (2014), 203–212.
33. Koren, M.J., Hunninghake, D.B., for the ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 44 (2004), 1772–1779.
34. LaRosa, J.C., Grundy, S.M., Waters, D.D., et al., for the TNT Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005), 1425–1435.
35. de Lemos, J.A., Blazing, M.A., Wiviott, S.D., for the A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes, phase Z of the A to Z trial. JAMA 292 (2004), 1307–1316.
36. Lincoff, A.M., Nicholls, S.J., Riesmeyer, J.S., et al., for the ACCELERATE Investigators. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 376 (2017), 1933–1942.
37. Marso, S.P., Bain, S.C., Consoli, A., et al., for the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
38. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al., for the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
39. Neal, B., Perkovic, V., Mahaffey, K.W., et al., for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
40. Pfeffer, M.A., Claggett, B., Diaz, R., et al., for the ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
41. Ridker, P.M., Everett, B.M., Thuren, T., et al., for the CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.
42. Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
43. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al., for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
44. Zinman, B., Wanner, C., Lachin, J.M., et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
45. Rogers, J.K., McMurray, J.J., Pocock, S.J., Zannad, F., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J., Pitt, B., Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation 126 (2012), 2317–2323.
46. Rogers, J.K., Pocock, S.J., McMurray, J.J., et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail 16 (2014), 33–40.
47. Claggett, B., Pocock, S., Wei, L.J., Pfeffer, M.A., McMurray, J.J.V., Solomon, S.D., Comparison of time-to-first event and recurrent-event methods in randomized clinical trials. Circulation 138 (2018), 570–577.
48. Wei, L.J., Lin, D.Y., Weissfeld, L., Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 84 (1989), 1065–1073.
49. Li, Q.H., Lagakos, S.W., Use of the Wei-Lin-Weissfeld method for the analysis of a recurring and a terminating event. Stat Med 16 (1997), 925–940.
50. Andersen, P.K., Gill, R.D., Cox's regression model for counting processes: A large sample study. Ann Statist 10 (1982), 1100–1120.
51. Lin, D.Y., Wei, L.J., Yang, I., Ying, Z., Semiparametric regression for the mean and rate functions of recurrent events. J R Statist Soc 62 (2000), 711–730.
52. Rondeau, V., Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events. Biostatistics 8 (2007), 708–721.
53. Venø, S.K., Bork, C.S., Jakobsen, M.U., et al. Marine n-3 polyunsaturated fatty acids and the risk of ischemic stroke. Stroke 50 (2019), 274–282.
54. Yamano, T., Kubo, T., Shiono, Y., et al. Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study. J Atheroscler Thromb 22 (2005), 52–61.
55. Nishio, R., Shinke, T., Otake, H., et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis 234 (2014), 114–119.
56. Niki, T., Wakatsuki, T., Yamaguchi, K., et al. Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound. Circ J 80 (2016), 450–460.
57. Schwartz, G.G., Steg, P.G., Szarek, M., et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379 (2018), 2097–2107.